spiriva respimat 2.5 µg inhal. sol. cartr.
boehringer ingelheim international gmbh - tiotropium bromide monohydrate 3,124 µg/dose - eq. tiotropium 2,5 µg/dose - inhalation solution - 2,5 mcg - tiotropium bromide monohydrate - tiotropium bromide
spiriva respimat 2.5micrograms/dose inhalation solution refill cartridge
boehringer ingelheim ltd - tiotropium bromide - inhalation solution - 2.5microgram/1dose
spiriva- tiotropium bromide capsule
a-s medication solutions - tiotropium bromide monohydrate (unii: l64sxo195n) (tiotropium - unii:0eb439235f) - spiriva handihaler (tiotropium bromide inhalation powder) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. spiriva handihaler is indicated to reduce exacerbations in copd patients. spiriva handihaler is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, or any components of this product [see warnings and precautions (5.2)] . in clinical trials and postmarketing experience with spiriva handihaler, immediate hypersensitivity reactions, including angioedema (including swelling of the lips, tongue, or throat), itching, or rash have been reported [see warnings and precautions (5.2)]. risk summary the limited human data with spiriva handihaler use during pregnancy are insufficient to inform a drug-associated risk of adverse pregnancy-related outcomes. based on animal reproduction studies, no structural abnormalities were observed when tiotropium was
inspiolto respimat solution
boehringer ingelheim (canada) ltd ltee - tiotropium (tiotropium bromide monohydrate); olodaterol (olodaterol hydrochloride) - solution - 2.5mcg; 2.5mcg - tiotropium (tiotropium bromide monohydrate) 2.5mcg; olodaterol (olodaterol hydrochloride) 2.5mcg - antimuscarinics antispasmodics
spiriva respimat
pco manufacturing - tiotropium - inhalation solution - 2.5 microgram - tiotropium bromide
spiriva tiotropium 18 micrograms powder for inhalation (in capsule) blister pack
boehringer ingelheim pty ltd - tiotropium, quantity: 18 microgram (equivalent: tiotropium bromide monohydrate, qty 22.5 microgram) - inhalation, powder for - excipient ingredients: lactose monohydrate - spiriva is indicated for the long term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (copd). spiriva is indicated for the prevention of copd exacerbations.
spiriva respimat 2,5 mikrogramm lösung zur inhalation
spiolto respimat inhalation solution 2.5 microgram2.5 microgram per actuation
boehringer ingelheim singapore pte. ltd. - olodaterol hydrochloride 0.002736 mg/actuation eqv olodaterol; tiotropium bromide monohydrate 0.003124 mg/actuation eqv tiotropium - solution - olodaterol hydrochloride 0.002736 mg/actuation eqv olodaterol 0.0025 mg/actuation; tiotropium bromide monohydrate 0.003124 mg/actuation eqv tiotropium 0.0025 mg/actuation
spiriva- tiotropium bromide monohydrate capsule
physicians total care, inc. - tiotropium bromide monohydrate (unii: l64sxo195n) (tiotropium - unii:0eb439235f) - tiotropium bromide monohydrate 18 ug - spiriva handihaler (tiotropium bromide inhalation powder) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. spiriva handihaler is indicated to reduce exacerbations in copd patients. spiriva handihaler is contraindicated in patients with a hypersensitivity to ipratropium or tiotropium. in clinical trials and postmarketing experience with spiriva handihaler, immediate hypersensitivity reactions, including angioedema (including swelling of the lips, tongue, or throat), itching, or rash have been reported. teratogenic effects, pregnancy category c. there are no adequate and well-controlled studies in pregnant women. spiriva handihaler should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. no evidence of structural alterations was observed in rats and rabbits at inhalation tiotropium doses of up to approximately 660 and 6
spiriva respimat- tiotropium bromide inhalation spray spray, metered
boehringer ingelheim pharmaceuticals, inc. - tiotropium bromide anhydrous (unii: xx112xzp0j) (tiotropium - unii:0eb439235f) - tiotropium bromide 1.562 ug - spiriva respimat (tiotropium bromide) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. spiriva respimat is indicated to reduce exacerbations in copd patients. important limitation of use: spiriva respimat is not indicated for the relief of acute bronchospasm. spiriva respimat is a bronchodilator indicated for the long-term, once-daily, maintenance treatment of asthma in patients 6 years of age and older. important limitation of use: spiriva respimat is not indicated for the relief of acute bronchospasm. spiriva respimat is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, or any component of this product [see warnings and precautions (5.2)] . in clinical trials with spiriva respimat, immediate hypersensitivity reactions, including angioedema (including swelling of the lips, tongue, or throat), itching, or rash have been reported [see warning